199 related articles for article (PubMed ID: 11521796)
21. Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma.
Lazzarino M; Orlandi E; Montillo M; Tedeschi A; Pagnucco G; Astori C; Corso A; Brusamolino E; Simoncini L; Morra E; Bernasconi C
Ann Oncol; 1999 Jan; 10(1):59-64. PubMed ID: 10076723
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin's lymphoma: a National Cancer Institute of Canada Clinical Trials Group study.
Crump M; Couban S; Meyer R; Rudinskas L; Zanke B; Gluck S; Maksymiuk A; Hoskins P; Matthews S; Eisenhauer E
Leuk Lymphoma; 2002 Aug; 43(8):1581-7. PubMed ID: 12400600
[TBL] [Abstract][Full Text] [Related]
23. The role of topoisomerase-I inhibitors in the treatment of non-Hodgkin's lymphoma.
Cabanillas F
Semin Hematol; 1999 Oct; 36(4 Suppl 8):11-5. PubMed ID: 10622224
[TBL] [Abstract][Full Text] [Related]
24. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
Aydin S; Dührsen U; Nückel H
Ann Hematol; 2007 Apr; 86(4):271-6. PubMed ID: 17216473
[TBL] [Abstract][Full Text] [Related]
25. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
26. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
27. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.
Josting A; Rudolph C; Reiser M; Mapara M; Sieber M; Kirchner HH; Dörken B; Hossfeld DK; Diehl V; Engert A;
Ann Oncol; 2002 Oct; 13(10):1628-35. PubMed ID: 12377653
[TBL] [Abstract][Full Text] [Related]
28. Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease.
Hertzberg MS; Crombie C; Benson W; Taper J; Gottlieb D; Bradstock KF
Ann Oncol; 2003; 14 Suppl 1():i11-6. PubMed ID: 12736225
[TBL] [Abstract][Full Text] [Related]
29. Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma.
Machover D; Delmas-Marsalet B; Misra SC; Gumus Y; Goldschmidt E; Schilf A; Frénoy N; Emile JF; Debuire B; Guettier C; Farrokhi P; Boulefdaoui B; Norol F; Parquet N; Ulusakarya A; Jasmin C
Ann Oncol; 2001 Oct; 12(10):1439-43. PubMed ID: 11762817
[TBL] [Abstract][Full Text] [Related]
30. Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma.
Pro B; Hagemeister FB; McLaughlin P; Romaguera J; Rodriguez MA; Cabanillas F; Tiongson LP; Younes A
Leuk Lymphoma; 2006 Sep; 47(9):1818-21. PubMed ID: 17064994
[TBL] [Abstract][Full Text] [Related]
31. Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation.
Girouard C; Dufresne J; Imrie K; Stewart AK; Brandwein J; Prince HM; Pantolony D; Keating A; Crump M
Ann Oncol; 1997 Jul; 8(7):675-80. PubMed ID: 9296221
[TBL] [Abstract][Full Text] [Related]
32. Phase II trial of irinotecan (CPT-11) in relapsed or refractory non-Hodgkin's lymphomas.
Ribrag V; Koscielny S; Vantelon JM; Fermé C; Rideller K; Carde P; Bourhis JH; Munck JN
Leuk Lymphoma; 2003 Sep; 44(9):1529-33. PubMed ID: 14565655
[TBL] [Abstract][Full Text] [Related]
33. Infusional vinorelbine in relapsed or refractory lymphomas.
Sarris AH; Psyrri A; Hagemeister F; Romaguera J; McLaughlin P; Rodriguez MA; Bachier C; Younes A; Mesina O; Oholendt M; Medeiros LJ; Samuels B; Adams LM; Cabanillas F
Leuk Lymphoma; 2000 Oct; 39(3-4):291-9. PubMed ID: 11342309
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246.
Press OW; LeBlanc M; O'Rourke TJ; Gagnet S; Chapman RA; Balcerzak SP; Fisher RI
J Clin Oncol; 1998 Feb; 16(2):574-8. PubMed ID: 9469343
[TBL] [Abstract][Full Text] [Related]
35. Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphoma.
Younes A; Rodriguez MA; McLaughlin P; North L; Sarris AH; Pate O; Hagemeister FB; Romaguera J; Preti A; Bachier C; Cabanillas F
Leuk Lymphoma; 1997 Jun; 26(1-2):77-82. PubMed ID: 9250790
[TBL] [Abstract][Full Text] [Related]
36. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
Gómez H; Mas L; Casanova L; Pen DL; Santillana S; Valdivia S; Otero J; Rodriguez W; Carracedo C; Vallejos C
J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250
[TBL] [Abstract][Full Text] [Related]
37. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study.
Josting A; Sieniawski M; Glossmann JP; Staak O; Nogova L; Peters N; Mapara M; Dörken B; Ko Y; Metzner B; Kisro J; Diehl V; Engert A
Ann Oncol; 2005 Aug; 16(8):1359-65. PubMed ID: 15939712
[TBL] [Abstract][Full Text] [Related]
38. Phase I/II trial of cure-oriented high-dose chemoradiotherapy with transplantation of CD34+ peripheral blood stem cells purified by the immunomagnetic bead method for refractory hematological malignancies. Nagoya CD34+ PBSCT Study Group.
Ogura M; Kagami Y; Suzuki R; Miura K; Uehira K; Kurokawa T; Ito T; Kinoshita T; Emi N; Morishima Y; Kodera Y; Ueda R
Cancer Chemother Pharmacol; 1997; 40 Suppl():S51-7. PubMed ID: 9272135
[TBL] [Abstract][Full Text] [Related]
39. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study.
Kahl BS; Bailey HH; Smith EP; Turman N; Smith J; Werndli J; Williams EC; Longo WL; Kim KM; McGovern J; Jumonville A
Cancer Invest; 2005; 23(1):13-8. PubMed ID: 15779863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
